Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27259397 | 0.87 | FFAR1 (0.47) | L3MBTL1MCL1FFAR1 | |
| SCHEMBL13349555 | 0.84 | L3MBTL1 (0.43) | L3MBTL1FFAR4PPARGTSHRCYSLTR2 | |
| SCHEMBL13316456 | 0.79 | KMT2A (0.57) | L3MBTL1TSHRMAP4K4 | |
| SCHEMBL27259406 | 0.76 | TDP1 (0.48) | L3MBTL1PPARG | |
| SCHEMBL13316457 | 0.76 | TDP1 (0.48) | L3MBTL1PPARG | |
| SCHEMBL1806524 | 0.76 | L3MBTL1 (1.00) | L3MBTL1FFAR4TSHRMCL1MMP2 | |
| SCHEMBL27259726 | 0.72 | HTT (0.53) | L3MBTL1MCL1FFAR1 | |
| SCHEMBL27259375 | 0.72 | PTPN7 (0.43) | FFAR4TSHRFFAR1 | |
| SCHEMBL27259343 | 0.72 | PTPN7 (0.46) | L3MBTL1PPARGCYSLTR2CYSLTR1FFAR1 | |
| SCHEMBL27259321 | 0.72 | CTRC (0.47) | L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728007-B2 | Therapeutic amides | WAYNE STATE UNIVERSITY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7585863-B2 | Antitumor agents; such as (2-(4-(7-Chloro-2-quinoxalinyl)oxy)propionylamino ethansulfonic acid; {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic acid | WAYNE STATE UNIVERSITY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7507749-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090076073-A1 | THERAPEUTIC AMIDES | WAYNE STATE UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076073-A1 | THERAPEUTIC AMIDES | HDAC5, HDAC6, ASAH2 | L3MBTL1 2501/4885FFAR4 3038/4885PPARG 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.